American Journal of Kidney Diseases
Volume 50, Issue 1 , Pages 133-142 , July 2007

ACE Inhibitors and Persistent Left Ventricular Hypertrophy After Renal Transplantation: A Randomized Clinical Trial

Part of this study was presented orally at the 2007 World Congress of Nephrology, Rio de Janeiro, Brazil, April 21-25, 2007, and published in abstract form in the Proceedings of the Congress.

  • Ernesto Paoletti, MD

      Affiliations

    • Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria S. Martino, Genova, Italy.
    • Corresponding Author InformationAddress correspondence to Ernesto Paoletti, MD, Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria S. Martino, Lgo R. Benzi 10, 16132, Genova, Italy.
    • ,
  • Paolo Cassottana, MD

      Affiliations

    • Divisione di Cardiologia. Azienda Ospedaliera Universitaria S. Martino, Genova, Italy.
    • ,
  • Marco Amidone, MD

      Affiliations

    • Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria S. Martino, Genova, Italy.
    • ,
  • Maurizio Gherzi, MD

      Affiliations

    • Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria S. Martino, Genova, Italy.
    • ,
  • Davide Rolla, MD

      Affiliations

    • Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria S. Martino, Genova, Italy.
    • ,
  • Giuseppe Cannella, MD, PhD

      Affiliations

    • Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria S. Martino, Genova, Italy.

Received 1 November 2006 ,Accepted 13 April 2007.

References 

  1. Rigatto C, Parfrey P. Therapy insights: Management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol. 2006;2:514–526
  2. Rigatto C, Foley RN, Jeffery J, et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol. 2003;14:462–468
  3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S112–S119
  4. Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation. 1995;60:908–914
  5. Hernandez D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int. 2000;58:889–897
  6. Midtvedt K, Ihlen H, Hartmann A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: A prospective randomized double-blind study. Transplantation. 2001;72:107–111
  7. London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease (Comparative effects of ACE inhibition and calcium channel blockade). Circulation. 1994;90:2786–2796
  8. Cannella G, Paoletti E, Delfino R, et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis. 1997;30:659–664
  9. Ferrara LA, Vaccaro O, Cardoni O, et al. Indexation criteria of left ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens. 2005;18:1263–1265
  10. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  11. Sahn DJ, De Maria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
  12. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necroscopy findings. Am J Cardiol. 1986;57:450–458
  13. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:2768–2774
  14. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550–1558
  15. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889–899
  16. Molkentin JD, Lu JR, Antos CR, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215–228
  17. Zhang W, Kowal RC, Rusnak F, et al. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res. 1999;84:722–728
  18. Sakata Y, Masuyama T, Yamamoto K, et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation. 2000;102:2269–2275
  19. Chang RK, Alzona M, Alejos J, et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Am J Cardiol. 1998;81:1277–1280
  20. Coley KC, Verrico MM, McNamara DM, et al. Lack of tacrolimus-induced cardiomyopathy. Ann Pharmacother. 2001;35:985–989
  21. Lee DBN. Cyclosporine and the renin-angiotensin axis. Kidney Int. 1997;52:248–260
  22. Schmieder RE, Lagenfeld MRW, Friedrich A, et al. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation. 1996;94:1304–1309
  23. Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13:564–569
  24. Covic A, Mardare N, Gusbeth-Tatomir P, et al. Acute effect of CyA A (Neoral) on large artery hemodynamics in renal transplant patients. Kidney Int. 2005;67:732–737
  25. London GM, Pannier B, Vicaut E, et al. Antihypertensive effects and arterial hemodynamic alterations during angiotensin converting enzyme inhibition. J Hypertens. 1996;14:1139–1146
  26. Paoletti E, Cassottana P, Bellino D, et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis. 2002;40:728–736
  27. Shimamoto H, Shimamoto Y. Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Hypertension. 1996;28:457–463

 Trial registration: http://isrctn.org; study number: ISRCTN94487168.Originally published online as doi:10.1053/j.ajkd.2007.04.013 on June 1, 2007.

PII: S0272-6386(07)00734-2

doi: 10.1053/j.ajkd.2007.04.013

American Journal of Kidney Diseases
Volume 50, Issue 1 , Pages 133-142 , July 2007

Article Tools

* Image Usage & Resolution